Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

5.250 +0.360 (+7.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces $75 million Private Placement
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
From Verastem Oncology
Via Business Wire
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
From Applied Therapeutics
Via GlobeNewswire
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.